Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyChristine E. Brown, Behnam Badie, Julie R. Ostberg et al.|New England Journal of Medicine|2016Cited by 1.8k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent GlioblastomaChristine E. Brown, Michael C. Jensen, Behnam Badie et al.|Clinical Cancer Research|2015Cited by 754
Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795Lingyu Li, Francesco M. Marincola, Yuan Gao et al.|Journal of Translational Medicine|2020Cited by 35